Abstract | BACKGROUND: this study aims to evaluate the efficacy of tixagevimab/ cilgavimab (Evusheld™) against various SARS-CoV-2 variants, including newer Omicron sublineages, in an immunocompromised cohort and in vitro. STUDY DESIGN: Conducted in Italy, this research involves immunocompromised patients who received Evusheld. It evaluates serum neutralization activity against different SARS-CoV-2 strains (20A.EU1, BA.5, BQ.1, XBB.1.5, XBB.1.16, and EG.5) before (T0), after 14 (T1), and after 30 (T2) days from the tixagevimab/ cilgavimab injection. Furthermore, the in vitro activity of Evusheld against SARS-CoV-2 VOCs was evaluated. RESULTS: The cohort was composed of 72 immunocompromised patients. The serum neutralizing activity of tixagevimab/ cilgavimab-treated patients was notably lower against newer variants such as BQ.1, XBB.1.5, XBB.1.16, and EG.5. Then, the in vitro study detailed specific EC50 values to quantify the activity of tixagevimab/ cilgavimab against various SARS-CoV-2 VOCs. Newer variants like BQ.1 and XBB.1.5 exhibited notably lower neutralization, underscoring the challenges in effectively countering the evolving virus. Interestingly, tixagevimab/ cilgavimab maintained reduced but still valid activity against EG.5 with an EC50 of 189 ng/mL and Cmax/EC90 of 110.7. CONCLUSIONS:
Tixagevimab/ cilgavimab efficacy wanes against novel subvariants. This underscores the critical need for ongoing adaptation and vigilance in prophylactic strategies to effectively counter the dynamic and unpredictable nature of the COVID-19 pandemic.
|
Authors | Anna Gidari, Samuele Sabbatini, Sabrina Bastianelli, Sara Pierucci, Chiara Busti, Elisabetta Svizzeretto, Andrea Tommasi, Carlo Pallotto, Elisabetta Schiaroli, Daniela Francisci |
Journal | Viruses
(Viruses)
Vol. 16
Issue 3
(Feb 25 2024)
ISSN: 1999-4915 [Electronic] Switzerland |
PMID | 38543720
(Publication Type: Journal Article)
|
Chemical References |
- tixagevimab
- cilgavimab
- Antibodies, Monoclonal
|
Topics |
- Humans
- COVID-19
(prevention & control)
- SARS-CoV-2
(genetics)
- Pandemics
- Antibodies, Monoclonal
|